We have demonstrated previously that the envelope protein of a murine retrovirus, Moloney murine leukaemia virus, has immunosuppressive properties in vivo. This property was manifested by the ability of the protein, when expressed by tumour cells normally rejected by engrafted mice, to allow the env-expressing cells to escape immune rejection and to proliferate. Here, it is shown that this property is not restricted to the envelope of a murine retrovirus, but is also shared by the envelope encoded by a primate retrovirus, MasonPfizer monkey virus.
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Mason-Pfizer monkey virus (MPMV) is a primate retrovirus that was first detected by electron microscopy in a mammary carcinoma of a female rhesus monkey Jensen et al., 1970) , from which it was molecularly cloned and characterized Sonigo et al., 1986 ). Yet, while some initial studies suggested that the virus could transform a number of simian cell lines (Fine et al., 1974) , the association with cancer has proved fleeting. Rather, newborn rhesus monkeys experimentally inoculated with this prototypic D-type retrovirus develop a wasting disease within a few weeks that is accompanied by opportunistic infections including pneumonia, enteritis and rashes (Fine et al., 1975 ; Bryant et al., 1986) . While the virus was widespread, post-mortem examination revealed only lymphadenopathy and thymic atrophy (Fine et al., 1975) . The coincidence of opportunistic infections and a thymic target suggested that the virus may exert a T cell-immunosuppressive effect, as has been suggested for other D-type retroviruses (Fine et al., 1975 ; Arthur et al., 1986 ; Bryant et al., 1986) . Infection by retroviruses is frequently associated with immune cell dysfunction. In the case of bona fide oncogenic retroviruses [e.g. feline leukaemia virus (FeLV) and Moloney murine Author for correspondence : Thierry Heidmann.
Fax j33 1 42 11 53 42. e-mail heidmann!igr.fr leukaemia virus (MoMLV)], it was strongly suggested that their envelope proteins have ' immunosuppressive ' effects, based essentially on a series of in vitro assays involving lymphocyte proliferative responses to mitogens (reviewed in Oostendorp et al., 1993 ; Haraguchi et al., 1997 ; see also Mathes et al., 1979 ; Cianciolo et al., 1980 ; Mangeney & Heidmann, 1998) . Here, we show that the MPMV envelope is actually immunosuppressive in vivo, using an assay involving rejection of tumour cells in immunocompetent mice, which further suggests that the MPMV envelope can inhibit the T cell response.
To assay the immunosuppressive activity of the MPMV envelope, we used the procedure that we devised previously (Mangeney & Heidmann, 1998) , which is illustrated in Fig.  1(a) . Murine tumour cells (MCA205 and CL8.1 cells ; see below) were transfected with an MPMV-env expression vector (pTMO ; Brody et al., 1994) (or an empty expression vector) and antibiotic-resistant cell populations were isolated. These cells expressed the stably transduced envelope vector, as illustrated in the RT-PCR analysis shown in Fig. 1 (b) . The cells were then engrafted into immunocompetent mice. In a first series of experiments, we used methylcholanthrene-induced murine fibrosarcoma cells (MCA205 ; H-2 b haplotype). Control tumour cells, when injected into an allogeneic host (five to ten BALB\c mice per group ; H-2 d haplotype), led to the development of small tumours, in only a limited number of engrafted animals (0-25 % ; Fig. 1 c, bottom) . Under the same conditions, the MCA205 cells expressing the MPMV envelope were able to form easily detectable tumours that persisted for at least 2 weeks in a large proportion of the engrafted animals ( 80 % ; Fig. 1 c, top) . This enhancement of tumour cell growth was not observed, under identical experimental conditions, with ' irrelevant ' expression vectors encoding transmembrane proteins unrelated to retroviral envelopes (the murine CD2 and erythropoietin receptor proteins ; data not shown) (Mangeney & Heidmann, 1998) . Induction of tumour formation was not due to any difference in intrinsic growth rates between the control and MPMV envelope-transduced cells, as tumour development induced by the two cell populations was identical when engrafted into a syngeneic host (C57BL\6, H-2 b haplotype) (Fig. 1 c, insets) .
In a second series of experiments, we used the CL8.1 The pTMO env-expressing vector containing the neomycin resistance gene (neo) has been described previously (Brody et al., 1994) , as have the cell types and experimental protocol used (Mangeney & Heidmann, 1998) . tumour cell line (H-2 b haplotype) to address a physiologically more relevant situation. Injection of these tumour cells into a syngeneic host (five to ten C57BL\6 mice per group ; H-2 b haplotype) led to the formation of small tumours, again in only a limited fraction of the engrafted animals (0-20 % ; Fig. 1 d,  bottom) , although they grew into large tumours in all cases when the mice were rendered immunodeficient by prior X-ray irradiation (see below). With MPMV envelope-transduced CL8.1 cells, we observed that expression of this envelope also severely enhanced tumour growth in mice (Fig. 1 d, top) : a large fraction of the immunocompetent mice ( 80 %) developed tumours, which grew continuously, leading to death. Again, tumour growth was not due to intrinsic differences in rates of proliferation between the envelope-transduced and control cells, as similar profiles were observed for the two cell types when engrafted into X-irradiated hosts (Fig. 1 d, insets) . Clearly, expression of the MPMV envelope gene, as demonstrated previously for the MoMLV envelope (Mangeney & Heidmann, 1998) , enables the transfected tumour cells to escape immune rejection in immunocompetent mice in both an allogeneic and a syngeneic context. Previous experiments, using synthetic peptides in vitro (Cianciolo et al., 1985 ; reviewed in Oostendorp et al., 1993 ; Haraguchi et al., 1997) , have suggested that a wellconserved domain of 17 amino acids, located within the transmembrane (TM) subunit of retroviral envelopes, might be responsible for the immunosuppressive effects. This domain can also be found in the MPMV envelope, at a position and with a sequence related to that of the well-characterized MoMLV sequence (yet with a five amino acid difference, see Fig. 2 a) . In order to analyse the possible role of this domain in the in vivo immunosuppressive effect of the MPMV envelope, we used the D33 mutant MPMV envelope, constructed and characterized by Brody & Hunter (1992) , which has 11 amino acids deleted from this domain (Fig. 2 a) . A remarkable feature of this construct is that the D33 deletion has no deleterious effect on the levels of protein synthesis and processing, the only major difference from the wild-type envelope being a loss of interaction between the surface (SU) and TM subunits of the envelope, resulting in the release of SU from the cell surface into the culture medium (Brody & Hunter, 1992 ; Brody et al., 1994 ; and data not shown) . Accordingly, an expression vector identical to the one for the wild-type MPMV envelope of the assay shown in Fig. 1 was used to transduce murine tumour cells with the mutant D33 envelope and to assay for tumour growth in mice. Interestingly, as illustrated in Fig. 2 (b) , the D33 mutant envelope still showed an immunosuppressive effect in the in vivo assay, although to a reduced extent compared with the wild-type envelope. This result indicates clearly that the so-called ' immunosuppressive ' domain is not the sole domain implicated in the in vivo immunosuppressive effect. This favours the involvement of several domains within the envelope protein, possibly dependent upon the overall structure of the protein. This would be consistent with the previously mentioned importance of peptide conformation for reported in vitro effects (Monell & Strand, 1994) , as well as for the much higher efficiency of complete envelope proteins versus peptides in these assays (Oostendorp et al., 1993) . Delineation of the effective domains involved in the immunosuppressive effect will probably be difficult, taking into account also that mutations within the TM moiety of retroviral envelopes are often deleterious for protein synthesis, stability or export (e.g. Brody & Hunter, 1992 ; Brody et al., 1994) .
The ability of type-D retroviruses to suppress the host immune response is well documented. In the case of SRV-1, a serotype of the type-D retroviruses that is 85 % homologous to MPMV, approximately 50 % of rhesus monkeys infected with the virus succumb to a fatal immunosuppressive disease . Similarly, newborn rhesus monkeys experimentally inoculated with MPMV as well as macaques naturally infected in primate centres and zoos die from opportunistic infections (Fine et al., 1975 ; Arthur et al., 1986 ; Bryant et al., 1986) . The present results therefore provide hints for the physiopathology of MPMV and further suggest strongly that the env gene per se could be the central, and possibly the sole, effector of immunosuppression. In fact, immunosuppression is likely to be a general strategy of retroviruses, also used by other pathogens, allowing efficient invasion of the host (see Oostendorp et al., 1993 ; Haraguchi et al., 1997 ; Naniche, 2000) . Our data also suggest that MPMV might be involved secondarily in a tumorigenic process, associated with a decreased efficiency of the immune system in the elimination of naturally occurring transformed cells. This could account for the fact that the MPMV was first isolated from a breast tumour (Jensen et al., 1970 ; under conditions where no other retrovirus could be detected (Bryant et al., 1986) , although MPMV is clearly not an oncogenic retrovirus sensu stricto.
